Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19641606 | 1.00 | RIPK1 (0.67) | RIPK1 | |
| SCHEMBL18366976 | 0.92 | RIPK1 (0.58) | RIPK1 | |
| SCHEMBL22888275 | 0.89 | RIPK1 (0.65) | RIPK1 | |
| SCHEMBL22209176 | 0.87 | RIPK1 (0.63) | RIPK1 | |
| SCHEMBL22209175 | 0.87 | RIPK1 (0.63) | RIPK1 | |
| SCHEMBL20213600 | 0.82 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL30015182 | 0.82 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL20228743 | 0.82 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL18367181 | 0.82 | RIPK1 (0.57) | RIPK1 | |
| SCHEMBL30014928 | 0.82 | RIPK1 (0.57) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| EP-3781571-B1 | N-[4-OXO-2,3-DIHYDRO-PYRIDO[3,2-B][1,4]OXAZEPIN-3-YL]-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOLE-2-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RIP1 KINASE INHIBITORS FOR TREATING E.G. IRRITABLE BOWEL SYNDROME (IBS) | HOFFMANN LA ROCHE (CH) | 2024-01-17 | — | — | EP | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023138433-A2 | AMIDE COMPOUND HAVING RIPK1 INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | GENENTECH, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3694858-B1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-01-11 | — | — | EP | disclosed |
| EP-4095138-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2022-11-30 | — | — | EP | disclosed |
| CN-110023313-B | Bicyclic amide compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-110072863-B | RIP1 kinase inhibitors and methods of use | 豪夫迈·罗氏有限公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2019072942-A1 | BICYCLIC COMPOUNDS FOR USE AS RIP1 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-04-18 | — | — | WO | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018109097-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-21 | — | — | WO | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2017004500-A9 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| WO-2017004500-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | RIPK1 3489/4885 |
| US-20180170927-A1 | INHIBITORS OF RIP1 KINASE AND METHODS OF USE THEREOF | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885 |
| US-20170008877-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | RIPK1 3064/4885 |
| US-11673892-B2 | Bicyclic compounds for use as RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.